Patient Case Review: Investigating Treatment Profiles, Exploring the Role of Treatment Adherence and Drug Class Selection Considerations

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Your daily dose of the clinical news you may have missed.

May 8th 2013

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

November 21st 2024

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

March 4th 2013

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

November 7th 2024

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

November 1st 2024

More than Half of US Adults Eligible for Semaglutide: Daily Dose

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Related Content

Sydney Jennings

December 9th 2024

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

Your daily dose of the clinical news you may have missed.

May 8th 2013

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

November 21st 2024

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

March 4th 2013

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

November 7th 2024

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

November 1st 2024